Novel indirubin derivatives, promising anti-tumor agents inhibiting cyclin-dependent kinases.
Merz
K H
KH
Food Chemistry and Environmental Toxicology, Technical University of Kaiserslautern, Germany.
Schwahn
S
S
Hippe
F
F
Mühlbeyer
S
S
Jakobs
S
S
Eisenbrand
G
G
D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D042846:CDC2-CDC28 Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D051357:Cyclin-Dependent Kinase 2; D004791:Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D005134:Eye Neoplasms / Q000188:drug therapy / Q000201:enzymology; D006801:Humans; D007211:Indoles / Q000494:pharmacology* / Q000627:therapeutic use; D010766:Phosphorylation / Q000187:drug effects; D012175:Retinoblastoma / Q000188:drug therapy / Q000201:enzymology; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D007211:Indoles; D042846:CDC2-CDC28 Kinases; C495894:CDK2 protein, human; D051357:Cyclin-Dependent Kinase 2; C027185:indirubin